Clinical trial NCT02278315: Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Official title: Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
Radiopharmaceutical
Therapy
Phase 1
Lead sponsor: Cellectar Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2014-10-30
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.

Detailed description: Multiple myeloma (MM) is an incurable, monoclonal proliferation of plasma cells. Approximately 80,000 Americans are affected by MM with approximately 22,000 new cases diagnosed and 11,000 deaths each year. The introduction of newer therapies in the past twenty years, such as autologous stem cell transplantation and novel agents such as proteasome inhibitors and immune modulating drugs has improved outcomes, with current median overall survival estimates of 3-10 years depending on a number of patient-, disease- and treatment-related factors. However, despite these innovations, myeloma relapse is inevitable. Therefore, there is a clear need for improved therapies for MM and, in particular, for relapsed disease.

I-131-CLR1404 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). Radioiodinated CLR1404 has been evaluated in over 60 xenograft and spontaneous (transgenic) tumor models. In all but two cases of hepatocellular carcinoma, CLR1404 demonstrated selective cancer cell uptake and retention. In various rodent tumor models, I-131-CLR1404 has also demonstrated tumor growth delay and prolongation of survival.

Based on the critical unmet medical need for effective agents with novel mechanisms of action in MM, the exquisite radiosensitivity of MM, and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess I-131-CLR1404 in a MM-specific phase 1 trial.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed multiple myeloma
* Prior treatment with or intolerance to proteasome inhibitor and immunomodulator
* Bone marrow biopsy within 28 days of study drug infusion demonstrating at least 5% plasma cell involvement
* Progressive disease defined by any of following:

  25% increase in serum M-protein from lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of \> or equal to 0.5 g/dL; 25% increase in urine M-protein from lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of \> or equal to 200 mg/24h; 25% increase in bone marrow plasma cell percentage from lowest response value during (or after) last therapy - absolute bone marrow plasma cell percentage must be \> or equal to 10% unless prior complete response when absolute bone marrow plasma cell percentage must be \> or equal to 5%; 25% increase in serum FLC level from the lowest response value during (or after) last therapy - the absolute increase must be \> 10 mg/dL; new onset hypercalcemia \> 11.5 mg/dL
* Measurable disease defined by any of following: Serum M-protein \> 1 g/dL; Urine M-protein \> 200 mg/24h; Serum free light chain (FLC) assay: involved FLC level \> or equal to 10 mg/dL provided serum FLC ratio is abnormal; subjects who are non-secretors will be considered on a case-by-case basis
* Eastern Cooperative Oncology Group performance status of 0 to 2
* Life expectancy of at least 6 months
* Have initiative and means to be compliant with protocol and within geographical proximity to make required study visits as judged by Investigator
* Subject or legal representative has ability to read, understand and provide written informed consent for study related procedures
* Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment
* Women of childbearing potential and men who are able to father a child, must agree to use an effective contraception method during study and for 12 months following study drug administration

Exclusion Criteria:

* Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below. Stable, tolerable Grade 2 adverse events may be allowed at discretion of Investigator
* Prior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 Gy
* Prior radioisotope therapy
* Prior total body or hemi-body irradiation
* Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon spinal cord
* Subject has any of following laboratory abnormalities: WBC \< 3000/uL; ANC \< 1500/uL; Hemoglobin \< 8 g/dL; Estimated glomerular filtration rate \< 30 mL/min/1.73 m2; ALT \> 3 x ULN ; Bilirubin \> 1.5 x ULN
* Platelet count \< 100,000/uL without full-dose anticogulation therapy
* Platelet count \< 150,000/uL with ongoing full-dose anticoagulation therapy
* Clinically significant bleeding event, as judged by investigator, within prior 6 months
* Chronic immunosuppressive therapy
* Anti-platelet therapy, except low-dose aspirin for cardioprotection
* PTT \> 1.3 x ULN
* INR \> 1.3
* Radiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 2 weeks of or after eligibility-defining bone marrow biopsy. Bisphosphonates and denosumab are permitted if subject has been receiving for at least 90 days
* History of hypersensitivity to iodine
* Any other concomitant serious illness or organ system dysfunction in opinion of Investigator would either compromise subject safety or interfere with test drug safety evaluation
* Major surgery within 6 weeks of enrollment
* Known history of HIV, hepatitis C or hepatitis B infection
* Pregnancy or breast-feeding

Primary outcomes:
measure: Number of participants with dose limiting toxicities (DLT)
timeFrame: up to 85 days
Secondary outcomes:
measure: Identification of recommended phase 2 dose of I-131-CLR1404 with concurrent weekly dexamethasone
timeFrame: until non-tolerated dose is defined; dose escalation descision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
measure: Identification of recommended phase 2 dose of I-131-CLR1404 without dexamethasone
timeFrame: until non-tolerated dose is defined; dose escalation descision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
measure: Identify the recommended dosing schedule of I-131-CLR1404, in relapsed or refractory MM
timeFrame: until non-tolerated dose is defined with both dosing regimens; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
Other outcomes:
measure: Determination of therapeutic activity of I-131-CLR1404 in relapsed or refractory multiple myeloma
timeFrame: through Day 85
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Maywood
country: United States
facility: Loyola University Medical Center
state: Illinois
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Madison
country: United States
facility: University of Wisconsin Hospital and Clinics
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Natalie S Callander, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014 Jun 11;6(240):240ra75. doi: 10.1126/scitranslmed.3007646.